查詢結果分析
來源資料
相關文獻
- 帶狀皰疹疼痛之中藥療法病案報告
- 維他命C在治療帶狀皰疹後神經痛之應用
- Management of Postherpetic Neuralgia in Stroke Patients: A Literature Review
- Case Report--Successful Treatment of Brush-evoked Pain Induced after Herpes Zoster by Trigger Point Injections with Botulinum Toxin A
- Post-Herpetic Neuralgia--Current Management and Prevention
- 水痘-帶狀皰疹的中西醫論治
- Starting Dose of Gabapentin for Patients with Post-herpetic Neuralgia--A Dose-response Study
- A Technical Note: Computed Tomography (CT)-Guided Percutaneous Coaxial Pulsed Radiofrequency for Post-Herpetic Neuralgia
- Impending Diabetic Ketoacidosis after Epidural Steroid and Local Anesthetics Administration for Herpes Zoster with Deafferentation Pain of a Diabetic Patient--A Case Report
- Extremely Prolonged Prodromal Pain Due to Herpes Zoster Mimicking Atypical Facial Pain
頁籤選單縮合
| 題 名 | Starting Dose of Gabapentin for Patients with Post-herpetic Neuralgia--A Dose-response Study=Gabapentin治療帶狀皰疹後神經痛的起始劑量--一個藥物劑量反應研究 |
|---|---|
| 作 者 | 簡維宏; 吳佳展; 莫世湟; 孫維仁; | 書刊名 | 麻醉學雜誌 |
| 卷 期 | 43:2 民94.06 |
| 頁 次 | 頁73-77 |
| 分類號 | 416.5 |
| 關鍵詞 | 帶狀皰疹; 神經痛; Gabapentin; Herpes zoster; Neuralgia; |
| 語 文 | 英文(English) |
| 中文摘要 | 背景:許多研究顯示,gabapentin可用於治療帶狀皰疹後神經痛,在每天1200 mg至2400 mg的劑量下,可以提供最大的止痛效果,然而起始劑量的使用,並沒有相關的研究。本篇的研究目的,在於建立治療帶狀皰疹後神經痛的起始劑量。方法:這是一個臨床隨機時序性的研究,將病人隨機分成三組,分別接受每天200 mg、400 mg或600 mg的gabapentin連續三天。分別在第0天與第3天評估止痛效果以及眩暈、欲睡和疲倦等副作用。結果:總共有61位病人參與研究計畫,32位男性29位女性。在三天的治療後,三組病人的疼痛都有獲得改善(P<0.05)。副作用方面,接受不同劑量的三組病人,眩暈、欲睡和疲倦的程度並沒有差異(P>0.05)。結論:研究結果顯示在前三天的治療,接受gabapentin 200 mg、400 mg或600 mg的病人,疼痛都有相當的減緩與最少的副作用。所以,每天200 mg的最低起始劑量,並不能提供減少副作用的效果時,我們建議以gabepentin每天600 mg的起始劑量,可以安全有效的使用於病人上。 |
| 英文摘要 | Background: Gabapentin has been shown to provide pain relief for post-herpetic neuralgia at dosage of 1,200 to 2,400 mg/day. However, the initial dosing strategy has not been thoroughly investigated. The purpose of this study was to establish the initial dosing strategy in the treatment of the gabapentin-naive patients with post-herpetic neuralgia. Methods: This clinical study was an open-label, randomized, time-sequence and controlled trial. Each gabapentin-naive subject was allocated to receive either 200 mg (100 mg, twice daily), 400 mg (100 mg, four times daily), or 600 mg (200 mg, three times daily) of gabapentin for three days. The analgesic effect and occurrence of dizziness, drowsiness, and fatigue were assessed at day 0 and day 3. Results: A total of 61 subjects (32 male/29 female) were enrolled in this study. The intensity of pain was greatly improved in all three groups after three days of treatment (visual analog scale decreased from 6.5±1.6 to 4.5±2.1, P<0.05). There was no statistically significant difference among subjects taking 200 mg, 400 mg, or 600 mg with respect to dizziness, drowsiness or fatigue. Conclusions: This study shows that elderly gabapentin-naive subjects no matter whether receiving 200, 400 or 600 mg/day of gabapentin benefited a moderate pain relief with minimal side effects at the first three days of treatment Since starting with a minimal dose of 200 mg/day did not offer a better reduction of side effects, we suggest that 600 mg/day gabapentin could be a safe and effective starting dose for patients with post-herpetic neuralgia. |
本系統中英文摘要資訊取自各篇刊載內容。